Kodiak spikes as J.P. Morgan upgrades on eye disease drug, KSI-101
Source: SeekingAlpha
2025-10-24 09:16:06 ET
More on Kodiak Sciences
- Kodiak Sciences: Odds May Be Narrowing For Longer Lasting Eye Disease Med Approval
- Kodiak gains as Barclays upgrades on Roche data for eye disease drug
- Seeking Alpha’s Quant Rating on Kodiak Sciences
- Historical earnings data for Kodiak Sciences
- Financial information for Kodiak Sciences
Read the full article on Seeking Alpha
For further details see:
Kodiak spikes as J.P. Morgan upgrades on eye disease drug, KSI-101
Kodiak Sciences Inc
NASDAQ: KOD
KOD Trading
1.61% G/L:
$23.65 Last:
162,877 Volume:
$23.66 Open:
KOD Latest News
March 09, 2026 10:06:30 am
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing
February 19, 2026 05:34:01 pm
Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead
KOD Stock Data
$1,412,241,980
32,435,700
0.8%
39
N/A
Biotechnology & Life Sciences
Healthcare
US
Palo Alto
